ERBB2 and breast carcinoma: The occurrence of brain metastases in patients with HER2-positive breast cancer is an important factor affecting patient survival, and considerable efficacy has been achieved with current drug treatments, including large-molecule monoclonal antibodies, ADCs, and small-molecule TKI drugs.